Prostate extract after transurethral resection for benign prostatic hyperplasia
V. N. Pavlov, A. A. Kazikhinurov, R. A. Kazikhinurov, S. Sh. Sabirzyanov, Yu. D. Saleeva, K. A. Kazikhinurova · 2022 · Urologiia. 2022;(6):42–46.
Study findings
Urinary symptom, quality-of-life and urine-flow measures improved in both postoperative groups. The Prostateks adjunct group reported larger improvements at one and three months.
- Population and setting
- 127 men after bipolar prostate resection: adjunctive Prostateks 60, tamsulosin-only comparison 67
- Evidence type
- Human comparative study
- Preparation
- See the original report; formulation details require verification.
- Source language
- English abstract; original language varies
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Randomization and blinding are not established in the abstract. Surgery and tamsulosin are co-interventions.
- The discussion’s comparison with another branded product is not a randomized head-to-head equivalence trial.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Publisher English abstract checked; full paper not appraised.
Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.
Citation and original source
Original source: V. N. Pavlov, A. A. Kazikhinurov, R. A. Kazikhinurov, S. Sh. Sabirzyanov, Yu. D. Saleeva, K. A. Kazikhinurova. Prostate extract after transurethral resection for benign prostatic hyperplasia Urologiia. 2022;(6):42–46. 2022.
Molekul research summary: https://molekul.io/research/prostateks-turp-2022. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry